Find Clinical Trial
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19
← Back
| Study Phase |
Phase 1 |
| Therapeutic Area |
Cancers |
| Indication | Blood cancer |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
UCART19, |
| Active Substance Code | S068587 |
| Protocol Code | CL1-68587-003 |
| EudraCT Code | 2016-000297-38 |
| NCT Code | NCT02735083 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
More information
UCART-19 is anti-CD-19 allogenic CAR-T product developed based on exclusive license granted by Cellectis to Servier. UCART-19 uses Cellectis’ technologies, including TALEN® gene-editing technologies |
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
